Megan L Gow1,2, Louise A Baur3,4, Nathan A Johnson5, Chris T Cowell6,7, Sarah P Garnett3,6,7. 1. Discipline of Child and Adolescent Health, University of Sydney, Sydney, NSW, Australia. megan.gow@health.nsw.gov.au. 2. Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead, Corner of Hawkesbury Road and Hainsworth Street, Locked Bag 4001, Westmead, NSW, 2145, Australia. megan.gow@health.nsw.gov.au. 3. Discipline of Child and Adolescent Health, University of Sydney, Sydney, NSW, Australia. 4. The Children's Hospital at Westmead Clinical School, The Children's Hospital at Westmead, Sydney, NSW, Australia. 5. Faculty of Health Sciences, University of Sydney, Sydney, NSW, Australia. 6. Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead, Corner of Hawkesbury Road and Hainsworth Street, Locked Bag 4001, Westmead, NSW, 2145, Australia. 7. Kids' Research Institute, The Children's Hospital at Westmead, Sydney, NSW, Australia.
Abstract
AIMS/HYPOTHESIS: The aim of the study was to investigate whether a very-low-energy diet (VLED) is a feasible and acceptable treatment option for type 2 diabetes in children and adolescents, and whether adherence can lead to rapid weight loss, reversal of type 2 diabetes and reduced liver fat as seen in adult studies. METHODS: Eight participants with type 2 diabetes and obesity, aged 7-16 years, non-medicated (n = 1) or treated with metformin (n = 7) and in some cases insulin (n = 3), followed a VLED (<3360 kJ/day) for 8 weeks, then transitioned to a hypocaloric diet (∼6300 kJ/day) that they followed to 34 weeks. HbA1c, fasting glucose and 2 h post-glucose load plasma glucose (2hG) were determined from fasting blood and an OGTT. Liver fat concentration was quantified using proton magnetic resonance spectroscopy. Adherence was defined as ≥5% weight loss during the 8 week VLED. RESULTS: Adherers (n = 5) and non-adherers (n = 3) had median weight loss of 7.5% and 0.5%, respectively, at 8 weeks. Overall, HbA1c (mean [SE] 8.1% [0.7%] to 6.6% [0.5%]; p = 0.004) and 2hG (15.6 [1.6] mmol/l to 11.3 [1.0] mmol/l; p = 0.009) were significantly reduced at 8 weeks compared with baseline. Liver fat was also significantly reduced from baseline (14.7% [2.2%]) to 8 weeks (5.8% [1.7%]; p = 0.001). Only three out of eight participants met non-alcoholic fatty liver disease (NAFLD) criteria (≥5.5%) at 8 weeks, compared with eight out of eight at baseline. The three participants on insulin therapy at baseline were able to cease therapy during the 8 week VLED. At 34 weeks, adherers (n = 5) achieved 12.3% weight loss, none met NAFLD criteria and four did not meet American Diabetes Association criteria for type 2 diabetes. CONCLUSIONS/ INTERPRETATION: A VLED appears to be a feasible treatment option for some youth with type 2 diabetes on metformin therapy. Youth who agree to participate and adhere to a VLED achieve rapid weight loss, dramatic reductions in liver fat and reversal of type 2 diabetes. This highlights the capacity of a VLED to be used as a first-line treatment option in newly diagnosed youth. A larger trial with a control group and longer follow-up will be required to encourage a change in standard treatment. TRIAL REGISTRATION: Australian New Zealand Clinical Trial Registration Number (ACTRN) ACTRN12616000375459 ( www.ANZCTR.org.au/ACTRN12616000375459.aspx ).
AIMS/HYPOTHESIS: The aim of the study was to investigate whether a very-low-energy diet (VLED) is a feasible and acceptable treatment option for type 2 diabetes in children and adolescents, and whether adherence can lead to rapid weight loss, reversal of type 2 diabetes and reduced liver fat as seen in adult studies. METHODS: Eight participants with type 2 diabetes and obesity, aged 7-16 years, non-medicated (n = 1) or treated with metformin (n = 7) and in some cases insulin (n = 3), followed a VLED (<3360 kJ/day) for 8 weeks, then transitioned to a hypocaloric diet (∼6300 kJ/day) that they followed to 34 weeks. HbA1c, fasting glucose and 2 h post-glucose load plasma glucose (2hG) were determined from fasting blood and an OGTT. Liver fat concentration was quantified using proton magnetic resonance spectroscopy. Adherence was defined as ≥5% weight loss during the 8 week VLED. RESULTS: Adherers (n = 5) and non-adherers (n = 3) had median weight loss of 7.5% and 0.5%, respectively, at 8 weeks. Overall, HbA1c (mean [SE] 8.1% [0.7%] to 6.6% [0.5%]; p = 0.004) and 2hG (15.6 [1.6] mmol/l to 11.3 [1.0] mmol/l; p = 0.009) were significantly reduced at 8 weeks compared with baseline. Liver fat was also significantly reduced from baseline (14.7% [2.2%]) to 8 weeks (5.8% [1.7%]; p = 0.001). Only three out of eight participants met non-alcoholic fatty liver disease (NAFLD) criteria (≥5.5%) at 8 weeks, compared with eight out of eight at baseline. The three participants on insulin therapy at baseline were able to cease therapy during the 8 week VLED. At 34 weeks, adherers (n = 5) achieved 12.3% weight loss, none met NAFLD criteria and four did not meet American Diabetes Association criteria for type 2 diabetes. CONCLUSIONS/ INTERPRETATION: A VLED appears to be a feasible treatment option for some youth with type 2 diabetes on metformin therapy. Youth who agree to participate and adhere to a VLED achieve rapid weight loss, dramatic reductions in liver fat and reversal of type 2 diabetes. This highlights the capacity of a VLED to be used as a first-line treatment option in newly diagnosed youth. A larger trial with a control group and longer follow-up will be required to encourage a change in standard treatment. TRIAL REGISTRATION: Australian New Zealand Clinical Trial Registration Number (ACTRN) ACTRN12616000375459 ( www.ANZCTR.org.au/ACTRN12616000375459.aspx ).
Authors: Sarah Steven; Kieren G Hollingsworth; Peter K Small; Sean A Woodcock; Andrea Pucci; Benjamin Aribisala; Ahmad Al-Mrabeh; Ann K Daly; Rachel L Batterham; Roy Taylor Journal: Diabetes Care Date: 2015-12-01 Impact factor: 19.112
Authors: Sarah Steven; Kieren G Hollingsworth; Ahmad Al-Mrabeh; Leah Avery; Benjamin Aribisala; Muriel Caslake; Roy Taylor Journal: Diabetes Care Date: 2016-03-21 Impact factor: 19.112
Authors: Maria I Constantino; Lynda Molyneaux; Franziska Limacher-Gisler; Abdulghani Al-Saeed; Connie Luo; Ted Wu; Stephen M Twigg; Dennis K Yue; Jencia Wong Journal: Diabetes Care Date: 2013-07-11 Impact factor: 19.112
Authors: Kimberley H Seear; Matthew P Lelievre; David N Atkinson; Julia V Marley Journal: Int J Environ Res Public Health Date: 2019-03-24 Impact factor: 3.390
Authors: Megan L Gow; Anna Pham-Short; Hiba Jebeile; Benjamin J Varley; Maria E Craig Journal: Diabetes Metab Syndr Obes Date: 2021-01-18 Impact factor: 3.168
Authors: Michelle I Cardel; Mark A Atkinson; Elsie M Taveras; Jens-Christian Holm; Aaron S Kelly Journal: JAMA Pediatr Date: 2020-06-01 Impact factor: 16.193